Climb bio, inc.CLYM.US Overview
US StockHealthcare
(No presentation for CLYM)
CLYM Overall Performance
CLYM AI Analysis & Strategy
CLYM Recent Performance
0.21%
Climb bio, inc.
0.81%
Avg of Sector
-1.14%
S&P500
CLYM PowerScanner
CLYM Key Information
CLYM Valuation Metrics
CLYM Earnings Table
CLYM Profile
Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases. It develops budoprutug, an anti-CD19 monoclonal antibody for various autoimmune diseases, including systemic lupus erythematosus and lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The company was formerly known as Eliem Therapeutics, Inc. and changed its name to Climb Bio, Inc. in October 2024. Climb Bio, Inc. was incorporated in 2018 and is headquartered in Wilmington, Delaware.